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The life cycle of human papillomaviruses (HPV) has evolved to be
intimately connected to the differentiation program of host epithelial
tissues (Meyers et al., 1992; Meyers et al., 1997; Taichman and
LaPorta, 1986). The development of the organotypic (raft) epithelial
culture system has allowed for the development on an in vitro culture
system capable of reproducing the complete HPV life cycle, including
the propagation of infectious viral particles (Alam et al., 2008;
McLaughlin-Drubin et al., 2004; McLaughlin-Drubin and Meyers,
2004; McLaughlin-Drubin et al., 2003; Meyers et al., 1992; Meyers et
al., 1997; Sen et al., 2004). The raft culture system has been used to
study in detail the steps in the HPV life cycle (Alam et al., 2008; Bedell
et al., 1991; Bodily et al., 2006; Bodily andMeyers, 2005; Frattini et al.,
1996; Grassmann et al., 1996; Mayer and Meyers, 1998; Ozbun and
Meyers, 1996; Ozbun and Meyers, 1997; Ozbun and Meyers, 1998a,b;
Ozbun and Meyers, 1999b; Sen et al., 2004). In addition, two recent
publications have shown that the replication andmaturation of native
virus in differentiating host tissue differs in signiﬁcant aspects from
particles made using pseudovirus/quasivirus technologies (Conway
et al., 2009a,b).Chimeric viruses are commonly used to compare genes from one
virus with the homologous genes from a related virus to determine
the similarities and differences of those genes. A chimeric virus
system can be used to assign a particular viral phenotype to a speciﬁc
gene or sequence. Another use of a chimeric virus system is to
discover the commonalities of related viral genes. In this article, we
used chimeric HPVs to test the hypothesis that, although the HPV18
and HPV16 capsid genes have a high amount of sequence homology,
there are type-speciﬁc domains affecting the interaction of the two
capsid proteins during virion morphogenesis.
Previously, we designed experiments to study whether the non-
structural genes from one HPV type could function with the structural
genes of another HPV type. In that study, we replaced the L1 and L2
capsid protein open reading frames (ORFs) from HPV type 18 (HPV18)
with the L1 and L2 capsid protein ORFs from HPV16 (Meyers et al.,
2002). The resulting HPV18/16 chimeric virus was able to carry out the
complete viral life cycle culminating in theproduction of infectious virus
after introduction into keratinocytes that were allowed to terminally
differentiate and stratify in raft culture. Antiserum raised against HPV16
virus-like particles (VLPs) and not HPV18 VLPs speciﬁcally neutralized
the HPV18/16 chimeric virus (Meyers et al., 2002). This study
established the use of a viable chimeric virus replication system to
studyHPV genetics and conﬁrmed the ability of the nonstructural genes
of HPV18 to function with the structural genes of HPV16.
To extend these studies, we replaced either the L1 capsid ORF of
HPV18 with that of HPV16 L1 or the L2 capsid ORF of HPV18 with that
of HPV16 L2. Chimeric HPV18 containing the HPV16 L1 ORF were able
to behave similar to wild-type HPV18 in that they completed the viral
life cycle in terminally differentiating raft tissue with the production
of infectious chimeric viral particles. However, while chimeric HPV18
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was maintained in an episomal state, induced a transformed
phenotype in raft culture, ampliﬁed viral DNA (vDNA), and HPV18
L1 and the HPV16 L2 capsid gene expression appeared normal in raft
cultures, we were unable to detect the production of infectious virus
from this chimera. In an effort to begin to narrow down the region of
the HPV18 L1 or HPV16 L2 capsid gene responsible for the
interference of production of infectious particles, we analyzed
chimeric exchanges of only half of the L1 or L2 capsid gene ORF of
HPV18 with that of HPV16. These studies identiﬁed the N-terminus of
the L1 capsid protein of HPV18 to be inhibitory to the production of
infectious chimeric virus containing the HPV16 L2 capsid gene.
Results
L2 and L1 chimeric viruses
Previously, to investigate whether the nonstructural genes of one
HPV type could cooperate with the structural genes of a second HPV
type during the complete viral life cycle, we constructed a recombi-
nant plasmid consisting of the URR and the nonstructural early gene
ORFs of HPV18 and the structural late gene ORFs of HPV16 (Meyers et
al., 2002). This chimeric virus behaved similar to wild-type HPV18 or
HPV16 maintaining 50–100 episomal genomes copies in infected
cells; on differentiation in the organotypic raft culture system, late
viral functions, including capsid gene expression and infectious virus
propagation, were observed (Meyers et al., 2002). These data
demonstrated that the nonstructural genes of HPV18 function with
the structural genes of HPV16, allowing the complete HPV life cycle to
occur. In the present study, we hypothesized that the structural genes
of one viral type contain domains that may affect intertype
interactions during the viral life cycle and virion morphogenesis.
To test this hypothesis, it was necessary to create chimeric mutant
viruses exchanging either the L2 or the L1 ORF of HPV18 for the L2 or L1
ORF of HPV16. An initial problemwith creating these chimeric mutants
is that the L2 and L1ORFs of HPV18 andHPV16 overlap; therefore, direct
exchanges of one of the ORF would affect the other ORF (Fig. S1). To
overcome this situation, we ﬁrst created mutant viruses using PCR
technology to individually amplify each ORF, introducing appropriate
restriction enzyme sites and cloning the amplimers into the pHPV18L1/
L2Δ plasmid that lacks the L2 and L1ORFs (Meyers et al., 2002) (Fig. S1).
This created twomutantviral genomes; onewild-type forHPV18except
that the L2 and L1 ORFs do not overlap but are now separated by an
unique HindIII site, the second is similar to our previous reported
HPV18/16 chimera (Meyers et al., 2002), except that the HPV16 L2 and
L1 ORFs do not overlap but are now separated by an unique HindIII site
(Fig. S1).Wenamed thesemutantsHPV18-L2(18)L1(18) andHPV18-L2
(16)L1(16). Ourmain goalwas to determine if capsid proteins from two
different HPVs could cooperate to produce infectious virus, and if not,
thenwhat domain(s) of the protein is responsible. However, in creating
these mutant genomes, there was the possibility that the tandemFig. 1. Late functions of viral mutants with nonoverlapping L2 and L1 ORFs. Late viral life cycle
L2 and L1 ORFs; HPV18-L2(18)L1(18), HPV18-L2(16)L1(16), HPV18-L2(18)L1(16), and HPduplication of the putative L1 splice acceptor would interfere with
expression of the capsid protein and therefore the ability of these
mutants to produce infectious virus. Therefore, we ﬁrst analyzed the
mutants for their ability to correctly express the capsid proteins and
produce infectious virus.
Continuously infected cell lines were made using our standard
electroporation protocol previously reported (Conway et al., 2009a,b;
McLaughlin-Drubin et al., 2004; McLaughlin-Drubin and Meyers,
2004; McLaughlin-Drubin and Meyers, 2005; McLaughlin-Drubin et
al., 2003; Meyers et al., 2002; Meyers et al., 1997). Upon differenti-
ation in raft culture, these cell lines were tested for late viral functions
of viral genome ampliﬁcation by Southern blotting, capsid gene
expression by Western blotting, and propagation of infectious
progeny by a limited dilution RT–PCR titering assay. Wild type and
mutant viruses had a similar phenotype including viral titers when
late viral functions were analyzed (Fig. 1). This suggested that the
physical separation of the L2 and L1 ORFs had no signiﬁcant effect on
the viral life cycles. We concluded that construction of mutant viruses
having their capsid gene ORFs separated did not introduce any
adverse effects in the capsid protein expression and the production of
infectious virus. All mutant genomes for this section and throughout
this report were analyzed by restriction digestion and sequenced to
ensure they were correct. Here and throughout the article, three or
more independently derived virus-infected cell lines were tested, and
the results were always found to be similar.
We then proceeded to create two chimeric mutants by exchanging
the HPV18 L2 or L1 ORF for its counterpart from HPV16 (Fig. S1). We
named these mutants HPV18-L2(18)L1(16) and HPV18-L2(16)L1
(18). Cell lines continuously infected with each mutant were made as
described (Conway et al., 2009a,b; McLaughlin-Drubin et al., 2005;
McLaughlin-Drubin et al., 2004; McLaughlin-Drubin and Meyers,
2004; McLaughlin-Drubin et al., 2003; Meyers et al., 2002; Meyers et
al., 1997). Upon differentiation in raft culture, these cell lines were
tested for late viral functions of vDNA ampliﬁcation by Southern
blotting, capsid gene expression byWestern blotting, and propagation
of infectious progeny by Limited Dilution RT-PCR titering assay. Both
mutant viruses were similar to wild-type in their ability to amplify
their genomes and express their capsid genes, however, when
infectivity was measured by Limited Dilution RT-PCR titering,
HPV18-L2(18)L1(16) was capable of infectious virus synthesis similar
to wild-type, but the chimera HPV18-L2(16)L1(18) was not (Fig. 1).
Three individual continuously infected cell lines using three separate
batches of primary foreskin keratinocytes were originally made for
each of the mutants. To rule out the possibility that the particular
genetic background of the three batches of primary foreskin
keratinocytes were responsible for the lack of infectious virus
production, we created 17 more HPV18-L2(16)L1(18) continuously
infected cell lines for a total of 20 cell lines. Infectious virus was
undetectable in 19 of the 20 cell lines after growth in raft culture
(Table 3). Following growth in raft culture, we were able to detect
infectious virus with only 1 of the 20 cell lines, but detection was atfunctions were analyzed for the four mutant HPV18 viruses containing nonoverlapping
V18-L2(16)L1(18).
Fig. 3.Western blot of HPV L1 capsid protein expression with the L1-speciﬁc mAb H18.
L9. H18.L9 monoclonal antibody was used to detect L1 protein expression from
chimeric HPV-infected raft tissues. H18.L9 was raised against HPV18 L1 protein but
cross-reacts with HPV16 L1 protein. Protein isolated from chimeric HPV18/CRPV virus-
infected raft tissues, expressing the CRPV L2 and L1 capsid proteins was used as a
negative control. Protein isolated from wild-type HPV18-infected raft tissues was used
as a positive control. Protein isolated from virus-infected raft tissues were loaded, 90 or
120 µg to eachwell as labeled. Lanes 1 and 2: HPV18/CRPV-infected tissues; lanes 3 and
4: wild-type HPV18-infected tissues; lanes 5 and 6: HPV18-L2(18)L1(18)-infected
tissues; lanes 7 and 8: HPV18-L2(18)L1(16)-infected tissues; lanes 9 and 10: HPV18-L2
(16)L1(18)-infected tissues (cell line #1); lanes 11 and 12: HPV18-L2(16)L1(18)-
infected tissues (cell line #2); and lanes 13 and 14: HPV18-L2(16)L1(18)-infected
tissues (cell line #3). Note that lanes 9–14 represent three individually derived cell lines
of the same mutant, HPV18-L2(16)L1(18). Molecular weight markers are on the left.
The arrow indicates the position of the L1 protein.
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20 (Table 3). This shows that the chimeric HPV, HPV18-L2(16)L1(18),
was extremely inefﬁcient at propagating infectious virus. We
concluded that the low levels of infectious virus were a consequence
of cooperation between the HPV18 L1 protein and the HPV16 L2
protein.
The separation of the L2 and L1 ORFs in these two chimeric
mutants could potentially affect the splicing patterns of the mRNAs
encoding the late proteins. Therefore, the inability of HPV18-L2(16)L1
(18) to propagate infectious virus could be due to a lack or decrease in
capsid protein expression. We therefore compared capsid protein
expression of the mutant viruses to wild-type virus. For these
analyses, we included three separate isolates of the replication
deﬁcient mutant, HPV18-L2(16)L1(18) (Figs. 2–4). Two different
HPV18 L1-specific mAbs, H18.E20 and H18.L9 (Figs. 2–3), that cross-
react with the HPV16 L1 protein and one HPV16 L2 mAb that cross-
reacts with the HPV18 L2 protein, H16.4B4 (Fig. 4), were used. A
replication-competent chimeric HPV18/CRPV virus (HPV18 with the
capsid genes of CRPV) was used as a negative control. All HPV18/
HPV16 L2/L1 chimeric viruses, including the three separate isolates of
the replication incompetent virus HPV18-L2(16)L1(18), expressed
similar levels of L1 (Figs. 2–3) and L2 (Fig. 4) as compared to wild-
type HPV18. The physical separation of the two overlapping structural
ORFs did not interfere with capsid protein expression and therefore
the lack of infectivity observed with the HPV18-L2(16)L1(18) mutant
virus is not due to reduced capsid protein expression. At least three
separate batches were used for the Western analyses, and the results
were the same for each batch. Differentiating epithelium infectedwith
HPV18-L2(16)L1(18) produced assembled virion-like particles with
benzonase protected encapsidated viral genomes at levels similar to
wild-type levels (data not shown). Therefore, the lack of infectivity
was not due to the inability to form stable viral particles.
We concluded from these studies that part or all of the HPV18 L1
and/or the HPV16 L2 proteins were unable to mutually cooperate to
efﬁciently produce infectious virus. This led us to begin to characterize
the region(s) of these two proteins responsible for this inability to
cooperate.
L2 and L1 half and half chimeric viruses
Many secondary structures and functional domains have been
mapped in the L1 and L2 proteins (Fig. 5). It was not readily apparentFig. 2.Western blot of HPV L1 capsid protein expression with the L1-speciﬁc mAb H18.
E20. H18.E20 monoclonal antibody was used to detect L1 protein expression from
chimeric HPV-infected raft tissues. H18.E20 was raised against HPV18 L1 protein but
cross-reacts with HPV16 L1 protein. Protein isolated from chimeric HPV18/CRPV virus-
infected raft tissues, expressing the CRPV L2 and L1 capsid proteins was used as a
negative control. Protein isolated from wild-type HPV18 infected raft tissues was used
as a positive control. Protein isolated from virus-infected raft tissues were loaded, 90 or
120 µg to eachwell as labeled. Lanes 1 and 2: HPV18/CRPV-infected tissues; lanes 3 and
4: wild-type HPV18-infected tissues; lanes 5 and 6: HPV18-L2(18)L1(18)-infected
tissues; lanes 7 and 8: HPV18-L2(18)L1(16)-infected tissues; lanes 9 and 10: HPV18-L2
(16)L1(18)-infected tissues (cell line #1); lanes 11 and 12: HPV18-L2(16)L1(18)-
infected tissues (cell line #2); and lanes 13 and 14: HPV18-L2(16)L1(18)-infected
tissues (cell line #3). Note that lanes 9–14 represent three individually derived cell lines
of the same mutant, HPV18-L2(16)L1(18). Molecular weight markers are on the left.
The arrow indicates the position of the L1 protein.which structural or functional domainmayaccount for the inability of L1
and L2 to cooperate in the chimeric mutant HPV18-L2(16)L1(18).
Consequently, we decided to characterize potential inhibitory domains
by making HPV18 and HPV16 L2 or L1 chimeras containing the N-
terminal half of a protein fromone viral type and the C-terminal half of a
protein of the other viral type. We chose to use a homologous sequence
in the middle of the L2 and L1 proteins of HPV18 and HPV16 for the
chimeric junction, allowing for the maintenance of sequence and
structure around the junction sites (seeMaterials andmethods; Fig. S2;
Fig. 5). In total, at least three independently derived cell lines for each of
the eight chimeric mutant HPV genomes were created (Fig. S2).
Multiple continuously infected cell linesweremadewith each of the
eightmutant genomes and their abilities to transit the viral life cycle and
replicate infectious viral stocks were studied. When grown in raft
culture, all cell lines were able to differentiate, and their morphologies
were within the parameters we have observed for tissues infected withFig. 4. Western blot of HPV L2 capsid protein expression with the L2-speciﬁc mAb
H16.4B4. H16.4B4 monoclonal antibody was used to detect L2 protein expression from
chimeric HPV-infected raft tissues. H16.4B4 was raised against HPV18 L2 protein but
cross-reacts with HPV16 L2 protein. Protein isolated from chimeric HPV18/CRPV virus-
infected raft tissues, expressing the CRPV L2 and L1 capsid proteins was used as a
negative control. Protein isolated from wild-type HPV18-infected raft tissues was used
as a positive control. Protein isolated from virus-infected raft tissues were loaded, 90 or
120 µg to eachwell as labeled. Lanes 1 and 2: HPV18/CRPV-infected tissues; lanes 3 and
4: wild-type HPV18-infected tissues; lanes 5 and 6: HPV18-L2(18)L1(18)-infected
tissues; lanes 7 and 8: HPV18-L2(18)L1(16)-infected tissues; lanes 9 and 10: HPV18-L2
(16)L1(18)-infected tissues (cell line #1); lanes 11 and 12: HPV18-L2(16)L1(18)-
infected tissues (cell line #2); and lanes 13 and 14: HPV18-L2(16)L1(18)-infected
tissues (cell line #3). Note that lanes 9–14 represent three individually derived cell lines
of the same mutant, HPV18-L2(16)L1(18). Molecular weight markers are on the left.
The arrow indicates the position of the L2 protein.
Fig. 5. Capsid proteins L1 and L2 chimeric junctions. Shown are the approximate positions of the cloning junctions used for the L1 and L2 HPV18 and HPV16 chimeras. (A) Shown are
the three-dimensional monomeric structure of L1 (left) and the amino acid sequences of HPV16 and HPV18 L1 proteins beginning at the consensus methionine (right) as described
by Chen et al. (2000). On the three-dimensional structure, an oval shows the region on the F ß-sheet strand containing the chimeric junction. The position of the chimeric junction
can also be seen of the two-dimensional sequence inside of the box. The positions of the ß-sheets (capital letter only for the three-dimensional structure and ß-capital letter for the
sequence) and the helixes (h) are shown. (B) Shown are described functional regions of papillomavirus L2 proteins (Bossis et al., 2005; Fay et al., 2004; Florin et al., 2006; Florin et al.,
2002; Gornemann et al., 2002; Heino et al., 2000; Holmgren et al., 2005; Kamper et al., 2006; Kawana et al., 1999; Laniosz et al., 2007; Okun et al., 2001; Roden et al., 2001; Roden et
al., 1994b; Yang et al., 2003a; Yang et al., 2003b; Zhou et al., 1994). The chimeric junction is shown at its position in the center of the L2 protein.
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McLaughlin-Drubin andMeyers, 2004;Meyers et al., 2002;Meyers et al.,
1997). Southern blots of whole tissue DNA were ﬁrst probed with
HPV18-speciﬁc radiolabeled probes then stripped and reprobed with
HPV16-speciﬁc radiolabeled probes to demonstrate the presence of
both HPV18 and HPV16 DNA (Fig. 6). Undigested DNA showed
supercoiled (FI) and nicked (FII) genomic DNAs when probed with
either HPV18 or HPV16. Viral genomes digested with EcoRI and probed
withHPV18 or HPV16 demonstrated a linear (FIII) band consistentwith
a length of about 8 kb, the size of the HPV genomic DNA. Viral genomes
digested with BglII and probed with HPV18 showed a band consistent
with a length of approximately 4900 nt, the size of the URR and early
genes (E) of HPV18. Viral genomes digested with BglII and probed with
HPV18orHPV16 showed aband consistentwith a length of around3 kb,
representing the L2 and L1 ORFs (L) of the chimeric HPV (Fig. 6).
Southern blots of independently derived chimeric HPV-infected cell
lines showed similar results.
Titers of L2 and L1 half and half mutants
We next tested for infectious virus production. Putative viral
stocks were prepared as previously described (Alam et al., 2008;
Conway et al., 2009a,b; McLaughlin-Drubin et al., 2005; McLaughlin-
Drubin et al., 2004;McLaughlin-Drubin andMeyers, 2004;McLaughlin-Drubin et al., 2003;Meyers et al., 2002;Meyers et al., 1997). To measure
titers HaCaT cells were infected with 1:20, 1:100, 1:1000, 1:5000,
1:7500, and 1:10,000 dilutions of each viral preparation for 2 days,
total RNA was then harvested, and had nested RT–PCR to speciﬁcally
amplify the HPV18 early spliced viral mRNA E1^E4 transcript and an
internal cellular control mRNA β-actin. Nested RT–PCR produces a
269-bp HPV18 E1^E4 and a 429-bp β-actin product. At the lowest
dilution of virus, all of the half and half chimeric HPV genomes except
HPV18-L2(16)L1(18/16) were able to produce infectious virus in our
infectivity assay (Fig. 7 and Table 1). While HPV18-L2(18)L1(18/16)
was infectious at a titer of 5000, stocks of HPV18-L2(16)L1(16/18)
were somewhat less infectious having a titer of 1000 (Table 2).
HPV18-L2(16/18)L1(18), HPV18-L2(16/18)L1(16), HPV18-L2(18/
16)L1(18), and HPV18-L2(18/16)L1(16) all had a lower titer of 100
(Table 2). Finally, HPV18-L2(18)L1(16/18) only had a titer of 20
(Table 2). Multiple cell lines and viral stocks prepared from an
infected cell line were tested for titers with all giving similar results
for each particular mutant. This demonstrates that while the capsid
gene chimeras did not appear to affect many aspects of the viral life
cycle, there was a signiﬁcant effect on titers for some of the mutants.
At least three independently derived chimeric HPV-infected cell lines
were tested for their production of infectious titers after growing in
raft cultures. Titers in each case were found to be similar for each cell
line infected with the same chimeric virus.
Fig. 6. Southern (DNA) blot hybridization of chimeric HPV DNA-electroporated HFK cell
lines grown in monolayer cultures. Cell lines were analyzed for the episomal
maintenance, copy number, and integrity of the chimeric genomic DNA. Left panels:
The blots were probed with an HPV18-speciﬁc probe. Right panels: The blots were
stripped and reprobed with an HPV16-speciﬁc probe. Samples in lanes 1 and 4 were
undigested. Samples in lanes 2 and 5 were digested with EcoRI, a single cutter of the
chimeric genomes. Samples in lanes 3 and 6 were digested with BglII to separate the
capsid genes (late ORFs) from the rest of the viral genome (early ORFs). Indicated are
form I DNA (FI), form II DNA (FII), form II DNA (FIII), early ORFs (E), and late ORFs (L).
Table 1
Primers used for construction of mutant viruses.
Oligo name Direction Sequence 5′→3′
18a5′ 5′ GCTAGCAGATCTATGGTATCCCACCGTGCCGC
18L2gHin 3′ GCTAGCAAGCTTCTAGGCCGCCACAAAGCC
18L1hHin 5′ GCTAGAAAGCTTATGTGCCTGTATACACGG
18L1hBgl 3′ GCTAGCAGATCTTTACTTTCCTGGCACGTAC
16c5′ 5′ GCTAGCAGATCTATGCGACACAAACGTTCTGC
16L2eHin 3′ GCTAGCAAGCTTCTAGGCAGCCAAGAA
16L1fHin 5′ GCTAGCAAGCTTTTACAGCTTACGTTTTTTGCG
16L1fBgl 3′ GCTAGCAGATCTATGCAGGTGACTTTTATTTAC
CM B1 5′ GCTAGCGCTCTTCATGACAACCCGGCCTTTGAGCCTGTG
CM B2 3′ GCTAGCAAGCTTCTAGGCCGCCACAAAGCC
CM B3 5′ GCTAGCAGATCTATGCGACACAAACGTTCT
CM B4 3′ GCTAGCGCTCTTCATCATATGTAATAAGTTTAGTGGGAGT
CM C1 5′ GCTAGCAAGCTTATGTGCCTGTATACACGG
CM C2 3′ GCTAGCGCTCTTCCTCACGCCGTAAGCAAAAAAACATGGA
CM C3 5′ GCTAGCGCTCTTCGTGAACAAATGTTTGTTAGACATTTA
CM C4 3′ GCTAGCAGATCTTTACAGCTTACGTTTTTT
CM E1 5′ GCTAGCGCTCTTCATGATAATCCTGCATATGAAGGTATA
CM E2 3′ GCTAGCAAGCTTCTAGGCAGCCAAAGAGAC
CM E3 5′ GCTAGCAGATCTATGGTATCCCACCGTGCC
CM E4 3′ GCTAGCGCTCTTCGTCATATGTAATTAAAGAGGATGGACG
CM F1 5′ GCTAGCAAGCTTATGCAGGTGACTTTTATT
CM F2 3′ GCTAGCGCTCTTCCCTTCGTAAATAAAAAAATAAGCT
CM F3 5′ GCTAGCGCTCTTCGAAGGCAGCTTTTTGCTAGGCATTTT
CM F4 3′ GCTAGCAGATCTTTACTTCCTGGCACGTAC
CM N-35 5′ GCTAGCAAGCTTATGGTACACATTATTATTTGTGGC
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L1 gene
We looked for patterns to try to explain the differences in
efﬁciency of chimeric mutant infectious virus production. One pattern
we noticed (although unlikely to be the only pattern) was that
chimeric viruses HPV18-L2(18/16)L1(18), HPV18-L2(16)L1(18/16),Fig. 7. Infectivity assay of chimeric HPVs. Shown is a 2% agarose gel of nested RT–PCR-
ampliﬁed HPV18 E1^E4 and ß-actin. All assays were done with use 1:20 dilution of the
viral stock. Lane 1: negative control mock-infected; lane 2: positive control wild-type
HPV18; lane3:HPV18-L2(16)L1(18/16); lane4:HPV18-L2(18)L1(18/16); lane5:HPV18-
L2(18/16)L1(18); lane 6: HPV18-L2(18)L1(16/18); lane 7: HPV18-L2(16)L1(16/18);
lane8:HPV18-L2(16/18)L1(18); lane9:HPV18-L2(16/18)L1(16); and lane10:HPV18-L2
(18/16)L1(16). Positionsofß-actinandE1^E4 ampliﬁed sequencesare shownon the right.and HPV18-L2(16)L1(18) were all relatively inefﬁcient for virus
production, all had the C-terminus of HPV16 L2 and the N-terminus of
HPV18 L1 (Table 3). These results suggested that at least one type-
speciﬁc domain might reside in these regions affecting virion
morphogenesis. We compared the amino acid sequence of the L1s
of HPV16 and HPV18 and found that HPV18 L1 has an extra 35 amino
acids in its N-terminus compared to HPV16 (Fig. 8). To determine if
this extra 35 amino acids of HPV18 L1 affects the interaction of HPV16
L2 and HPV18 L1 during virion morphogenesis or infectivity resulting
in poor viral titers, we constructedmutants deleting the ﬁrst 35 amino
acids of HPV18 L1 designated HPV18-L2(18)L1(Δ18), HPV18-L2(16)
L1(Δ18), HPV18-L2(18/16)L1(Δ18), and HPV18-L2(16/18)L1(Δ18)
(Fig. S4). At least three independently derived cell lines were created
for each mutant virus. The loss of the 35 amino acids from the N-
terminus had no effect of the stability of the particles.
All Δ18 L1 mutants were able to maintain their genomes
episomally. The efﬁciency of the Δ18 L1 mutants for developing cell
lines capable of stable episomal maintenance was 100%, the same as
wild-type HPV18 (data not shown). All the tissues harboring HPV18
L1 N-terminal deletions were able to stratify and differentiate, with a
similar morphology to that of wild-type HPV18. When we checked
HPV mutant genome ampliﬁcation by Southern blot analyses, all Δ18
L1 mutants, HPV18-L2(18)L1(Δ18), HPV18-L2(16)L1(Δ18), HPV18-Table 2
Virus titers of HPV18/16 L2/L1 chimeras.
Mutant Titers Independent
measurementsa
Titer range Ave/SDb
Wt HPV18 7500 8 7500–10,000 8125/1157
HPV18-L2(18)L1(18/16) 5000 3 5000 5000/0
HPV18-L2(18)L1(16/18) 20 3 20 20/0
HPV18-L2(16)L1(18/16) b20 4 0 0/0
HPV18-L2(16)L1(16/18) 1000 3 1000 1000/0
HPV18-L2(18/16)L1(18) 100 5 0–100 20/44.7
HPV18-L2(18/16)L1(16) 100 3 20–100 73/46.2
HPV18-L2(16/18)L1(18) 100 3 100 100/0
HPV18-L2(16/18)L1(16) 100 3 100 100/0
a Number of independent measurements made for each HPV construct.
b Titer average/standard deviation.
Table 3
Mutant viruses containing the HPV16 L2 C-terminus and the HPV18 L1 N-terminus.
Virus Independently immortalized
lines (line/attemptsa)
Infectious virus-producing lines
(lines producing/total linesb)
Titers Independent
measurementsc
Titer
range
Ave/SDd
HPV18-L2(16)L1(18/16) 4/4 0/4 b20 4 0 0/0
HPV18-L2(18/16)L1(18) 5/5 1/5 100 5 0–100 20/44.7
HPV18-L2(16)L1(18) 20/20 1/20 20 20 0–20 1/4.5
a The number of established continuous immortalized cell lines created with the particular HPV chimera over the number of attempts to derive such a cell line.
b The number of cell lines able to produce measurable infectious virus over the number of established cell lines.
c Number of independent measurements made for each HPV construct.
d Titer average/standard deviation.
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amplify their genomes when grown in raft cultures (data not
shown). All independently derived lines infected with the same
mutant virus showed similar results.
Performing our standard infectivity assay we measured titers of
the Δ18 L1. Wild-type HPV18 had an infectious titer of 7500, and
HPV18-L2(18)L1(Δ18) had an infectious titer of 10,000 (Table 4). This
result shows that deletion of the HPV18 L1 35 amino acid N-terminus
did not greatly affect virus titers. However, when we compared the
Δ18 L1 chimeric mutants to their full-length counterparts, we
observed a 125-fold increase in viral titer between HPV18-L2(16)L1
(Δ18) (titer=2500) and HPV18-L2(16)L1(18) (titer=20) (Table 4).
This result demonstrates that the ﬁrst 35 amino acids in HPV18 L1 N-
terminus, through a presently unknown mechanism, affects a
necessary interaction of the HPV18 L1 protein and the HPV16 L2
protein resulting in lower viral titers. HPV18-L2(16)L1(18) was very
inefﬁcient in virus production, with only 1 out of 20 cell lines able to
produce infectious virus. The only cell line able to produce infectious
virus did so at the limit of the assay's ability to detect infection. After
deleting the ﬁrst 35 amino acids in HPV18 L1 N-terminus, the virus
titer was increased 75-fold when comparing HPV18-L2(18/16)L1
(Δ18) (titer=7500) and HPV18-L2(18/16)L1(18) (titer=100)
(Table 4). Similarly, a 25-fold increase in viral titer was observed
between HPV18-L2(16/18)L1(Δ18) (titer=2500) and HPV18-L2
(16/18)L1(18) (titer=100). Together, these results suggest that the
extra 35 amino acids of the HPV18 L1 N-terminus may cause a
structural distortion in a HPV16 L2 capsid structure, which was
relieved by deleting the HPV18 L1 N-terminus. These studies have
identiﬁed one type-speciﬁc sequence affecting with the interaction
between HPV16 L2 and HPV18 L1, resulting in lower levels of
infectious virus production. At least three independently derived
chimeric HPV-infected cell lines were tested for their production of
infectious titers after growing in raft cultures. Titers in each case were
found to be similar for each cell line infected with the same chimeric
virus. In addition, mutants containing the Δ18 L1 produced benzonase
protected genome encapsidated viral particles in numbers similar to
wild-type (data not shown). We realize that others have produced
VLPs, etc., using the consensus Met and splicing data suggest that
these extra 35 amino acids would not contribute to the structure ofFig. 8. Papillomavirus L1 N-terminus amino acid alignment. Potential starthe virus. However, our genetic analysis suggests that the N-terminal
35 amino acids do play a role in capsid structure.
Neutralization analyses of Δ18 L1 chimeric virus with L1
conformation-dependent antibodies
We hypothesized that changes in viral titers seen with the Δ18 L1
mutants (Table 4) were due to structural changes in the virus evoked
by themutation. To provide preliminary evidence that this may be the
case, we used conformation-dependent L1 monoclonal antibodies
(mAb) to measure changes in the infectivity neutralization associated
with the mutations. To test whether the capsid structure had been
affected, HPV18 L1 conformation-dependent antibodies H18.J4 and
H18.K2 were tested for their ability to neutralize infection by HPV18-
L2(18)L1(Δ18), HPV18-L2(16)L1(Δ18), HPV18-L2(18/16)L1(Δ18),
and HPV18-L2(16/18)L1(Δ18). Although the epitopes for these
monoclonals have not yet been mapped we know that the deleted
N-terminal 35 amino acid sequence cannot contain the epitope for
H18.J4 or H18.K2. This is because mAbs H18.J4 and H18.K2 were
raised against HPV18 L1 VLPs lacking the ﬁrst 61 amino acids (Fig. 8;
Bishop et al., 2007). Infection by wild-type HPV18, as expected, was
completely neutralized by both H18.J4 and H18.K2 (Fig. 9A).
Interestingly, all four mutants were neutralized by H18.J4 but not by
H18.K2 (Fig. 9A), suggesting that subtle but signiﬁcant changes were
affected by the removal of the N-terminal 35 amino acids from the
HPV18 L1 protein. Studies were repeatable with virus from indepen-
dently derived cell lines.
MAb binding to Δ18 L1 mutants
We reasoned that the lack of neutralization by the mAb H18.K2
was due to an inability to bind to the mutant particle or that the H18.
K2 may still be able to bind but unable to block infection due to a
change in conformation caused by the loss of the N-terminus 35
amino acids. To test whether the failure of neutralization correlated to
the loss of antibody binding by the conformation-dependent
antibodies, ELISAs were performed. To perform ELISA analysis, each
chimeric HPV was used as antigen with wild-type HPV18 serving as
the positive controls. Wells probed with an irrelevant mAb weret sites for high-risk HPVs and the ‘consensus’ methionine are boxed.
Table 4
Virus titers of HPV18 N-terminal 35 aa deletion mutants.
Mutant Titers Independent measurementsa Titer range Ave/SDb
Wt HPV18 7500 8 7,500–10,000 8125/1157
HPV18-L2(18)L1(Δ18) 10,000 3 10,000 10,000/0
HPV18-L2(16)L1(18) 20 20 0–20 1/4.5
HPV18-L2(16)L1(Δ18) 2500 3 2500 2500/0
HPV18-L2(18/16)L1(18) 100 5 0–100 20/44.7
HPV18-L2(18/16)L1(Δ18) 7500 3 7500 7500/0
HPV18-L2(16/18)L1(18) 100 3 100 100/0
HPV18-L2(16/18)L1(Δ18) 2500 3 2500 2500/0
a Number of independent measurements made for each HPV construct.
b Titer average/standard deviation.
Fig. 9. (A) Neutralization of chimeric HPVs. Shown is a 2% agarose gel of nested RT–PCR-
ampliﬁed HPV18 E1^E4 and ß-actin. Chimeric viruses were preincubated with the
indicated mAb, H18.J4 or H18.K2. Lane 1: negative control, mock-infected; lane 2:
positive control, wild-type HPV18; lanes 3 and 4: HPV18-L2(18)L1(Δ18); lanes 5 and
6: HPV18-L2(16)L1(Δ18); lanes 7 and 8: HPV18-L2(18/16)L1(Δ18); lanes 9 and 10:
HPV18-L2(16/18)L1(Δ18); lane 11: negative control, mock infected; lanes 12 and 13:
positive control, wild-type HPV18. Positions of ß-actin and E1^E4 ampliﬁed sequences
are shown on the right. (B) Relative binding of conformation-dependent HPV18 L1-
speciﬁc mAbs H18.J4 and H18.K2 to chimeric HPVs by ELISA assay. Relative binding
for each chimeric HPV was deﬁned as the difference between wells probed with
(A) H18.J4 or (B) H18.K2 and wells probed with an irrelevant mAb. Values shown
are means±standard errors of the means. Lane 1: wild-type HPV18; lane 2: HPV18-
L2(18)L1(Δ18); lane 3: HPV18-L2(16)L1(Δ18); lane 4: HPV18-L2(18/16)L1(Δ18);
and lane 5: HPV18-L2(16/18)L1(Δ18).
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measurement for each chimeric HPV was deﬁned as the difference
between wells probed with a L1 type-speciﬁc and a type-irrelevant
antibodies. We ﬁrst measured binding using the mAb H18.J4, which
was capable of neutralizing all of the Δ18 L1 mutants. As seen in
Fig. 9B, H18.J4 was able to bind to each of the Δ18 L1 mutants as well
or better than wild-type HPV18. We next measured the binding of
H18.K2, which was unable to neutralize the Δ18 L1 mutants (Fig. 9A).
With the exception of HPV18-L2(18/16)L1(Δ18), H18.K2 was still
able to bind to the other three Δ18 L1 mutants similar or better than
its binding to wild-type (Fig. 9B). Although the binding of H18.K2 was
more variable than what was seen with H18.J4. These results suggest
that the change in capsid structure evoked by the deletion of the N-
terminus 35 aa of the HPV18 L1 protein blocked the neutralizing
capacity of mAb H18.K2 but not necessarily its ability to bind to the
capsid. While not quantitative, the ELISA results demonstrated that at
least part of the chimeric capsid proteins were correctly folded and
could be recognized by conformation-dependent antibodies. These
results collectively demonstrate that the extra 35 aa on the HPV18 L1
N-terminus interferes with the ability of the HPV18 L1 and the HPV16
L2 to cooperate and properly assemble into infectious viral particles.
Studies were repeatable with virus from independently derived cell
lines.
Discussion
For these studies, we used the organotypic raft culture system to test
the chimeric mutants instead of coexpressing the viral structural
proteins in a simple and less demanding system such as VLP or
pseudovirus technology for several reasons. First, wewanted to test the
mutants in a system best capable of using the process of naturally
differentiating human epithelium bywhichHPV replicates itself in vivo.
Second, we have extensive experiencewith raft cultures in studying the
HPV life cycle and replication of infectious virus. Third, in two recent
publications, we have shown that the replication and maturation of
native virus in differentiating host tissue differs in signiﬁcant aspects
from particles made using pseudovirus/quasivirus technologies
(Conway et al., 2009a,b). When the two conserved L2 cysteines were
mutated in pseudo- or quasiviruses, the particles produced were
noninfectious (Campos and Ozbun, 2009; Gambhira et al., 2009).
When we tested the same mutations in native particles, not only were
the mutant viruses infectious but titers were enhanced signiﬁcantly
(Conway et al., 2009a). This showed that viral morphogenesis can differ
from particles formed in undifferentiating monolayer culture versus
native particles formed in differentiating host epithelium. Finally, we
have numerous other studies in the lab underway, including studies on
mechanisms of infectivity, neutralization and cross-neutralization
epitopes, disinfectant sensitivity, and microbicide sensitivity, all
demonstrating differences between particles made in monolayer
culture and native virus made in host epithelium.
Our laboratory has previously shown that both structural genes of
HPV16 could function with the nonstructural genes of HPV18 for virus
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determine if the structural proteins, L2 and L1, could cooperate to
produce infectious viral particles.We replaced either the L2 ORF or the
L1 ORF of HPV18 with the counterpart from HPV16. All aspects of the
viral life cycle examined including expression of the capsid proteins
and particle assembly were found to be similar to wild-type; however,
while the HPV18 L2 protein could function with the HPV16 L1 protein
to propagate infectious particles, the HPV16 L2 protein was not able
to cooperate with the HPV18 L1 protein for infectious particle
production.
In an effort to identify the regions of either theHPV18 L1 and/or the
HPV16 L2 protein involved in the inability to propagate infectious
virus, we made chimeras where only half of either the HPV18 L2 or L1
ORFs were exchanged for the complementary region of HPV16.
After testing the eight resulting viral chimeras, it appeared that
whenever the N-terminal of the HPV18 L1 was present in the chimera
with the C-terminal half of the HPV16 L2 protein, production of
infectious virus synthesis was compromised. After comparing the L1
proteinN-terminal sequences of HPV18 andHPV16, itwas noticed that
HPV18 had 35 unique amino acids on its L1 protein N-terminus. In
addition, when the L1 protein N-termini of HPV18 and HPV16 were
aligned with the N-termini of other papillomaviruses, both had
additional in-frame sequences on their N-termini when compared to
the other papillomaviruses. Speciﬁcally, HPV18 had an additional 61
amino acids and HPV16 had an additional 26 amino acids. In studies
where virus-like particles (VLP), pseudovirus, or quasivirus are used,
these extra sequences are deleted from the expression vectors used
and all L1 expression begins at the ‘consensus’ ATG (Browne et al.,
1988; Carter et al., 1991; Cason et al., 1994; Heino et al., 1995;
Kirnbauer et al., 1992; Kirnbauer et al., 1993; Nardelli-Haeﬂiger et al.,
1997; Rossi et al., 2000; Xi and Banks, 1991; Zhou et al., 1990; Zhou et
al., 1991a,b). While maps of HPV18 late gene mRNAs have yet to be
published, splicing studies of the HPV16 capsid ORFs have mapped a
splice acceptor at nt 5637 3′ to the ﬁrst in-frame ATG and 5′ to the
second ATG of the L1 ORF (Doorbar et al., 1990; Milligan et al., 2007).
Use of this splice acceptorwould remove the extra 26 amino acids from
the N-terminus of the HPV16 L1 protein. Evidence for the potential
expression of L1 proteins initiated from the ﬁrst ATG comes from a
recent publication from our laboratory (Conway et al., 2009b). In this
study, we demonstrated that native viral particles consisted of two L1
proteins of different sizes. Importantly, the slowermigrating second L1
protein is not present in pseudo/quasiviruses (Conway et al., 2009b).
While a posttranslational modiﬁcation is possible, the sizes of the two
proteins are consistentwith the larger being 26 amino acidsmore than
the smaller. It is possible that another splice acceptor 5′ of theﬁrst ATG
was missed in previous studies or it is also possible that the larger L1
protein expressed is translated from one of the several transcripts
containing both the L2 and L1 ORFs (Milligan et al., 2007). In
eukaryotic cells, initiation of translation can occur by a mechanism
of internal initiation where the ribosome is recruited to an internal
start site that can be a considerable distance downstream of the 5′
terminus of the RNA (Charnay et al., 2009; Jackson, 2000; Lin et al,
2009; Stoneley and Willis, 2004). Using the Kozak rules for
translational initiation, the upstream ATG of HPV18 is either
equivalent or superior to that for the downstream ATG (Kozak, 1989).
When the extra 35 amino acids (as compared to the L1 protein
from HPV16) in the N-terminus of the HPV18 L1 protein was deleted,
chimeric virus containing the L1 protein of HPV18 and the L2 protein
of HPV16 produce viral titers equivalent to wild-type. Therefore,
these results demonstrate that the ﬁrst 35 amino acids of HPV18 L1
N-terminus act as a type-speciﬁc sequence affecting the proper
interactions between HPV16 L2 and HPV18 L1.
HPV11 L1 has been shown to cooperate and form complexes with
L2 proteins of HPV5, 6b, 12, 16, 33, and canine oral PV type 1 (COPV1)
but not the L2s of either HPV1a or BPV1 (Finnen et al., 2003)
demonstrating type speciﬁcity in the interaction of L2 and L1. Anotherstudy suggested that viral type-restricted domains exist affecting the
cooperation between L1 and L2 of different PV types (Okun et al.,
2001).
The L1 protein has been shown to be involved in viral DNA binding,
cell surface binding, and nuclear localization (Day and Schiller, 2006;
Graham, 2006). All these known activities are concentrated in the
L1 C-terminus. So far, there are no known activities reported for the L1
N-terminus. In contrast to L1, the minor capsid protein L2 has been
shown to be multifunctional. For example, L2 is required to cooperate
with L1 and induce the localization of viral L1 proteins to nuclear
subdomain ND10 (Becker et al., 2003; Florin et al., 2002; Okun et al.,
2001). In addition, the L2 protein consists of interactive sequences for
the viral E2 protein (Finnen et al., 2003; Heino et al., 2000; Okun et al.,
2001), Hsc70 chaperones (Florin et al., 2004), β-actins (Yang et al.,
2003b), t-SNARE (Bossis et al., 2005), and cell surface receptors (Da
Silva et al., 2001; Giroglou et al., 2001; McMillan et al., 1999; Roden et
al., 1994a). Incorporation of L2 into the viral capsid also enhances the
VLP and pseudovirus assembly and infection (Holmgren et al., 2005).
In addition to biological activities, structural analysis of the HPV16
L1 VLP capsid has been characterized (Chen et al., 2000). Because the
HPV16 L1 VLP could be crystallized for analysis only after the ﬁrst 36
amino acids were deleted (the 26 that are all deleted in VLPs plus 9
more), the extreme L1 N-terminal fragment is missing and the
structure is unknown. By comparison to the structurally related major
capsid protein of SV40, the PV L1 N-terminus is proposed to project
into the groove between the capsomeres to help stabilize the
structure. The extra piece in HPV18 L1 N-terminus may be located
close to the capsid surface and form extra contacts with the minor
capsid protein to further stabilize the particle (Chen et al., 2000;
Modis et al., 2002). Notably, 19 out of the 35 extra amino acids are
hydrophobic. It is likely that this N-terminal sequence is buried inside
the capsid or deep in the groove between the capsomeres. HPV18 L1
conformation dependent monoclonal antibodies H18.J4 and H18.K2
were both highly efﬁcient at neutralizing infection of wild-type
HPV18 and HPV18-L2(18)L1(18) virus. All four chimeras with the
HPV18 L1 N-terminal 35 amino acids deleted were neutralized by
H18.J4 but not by H18.K2. The epitope recognized by H18.K2 cannot
be contained within the deleted 35 amino acids because this sequence
was not part of the VLP used to produce H18.K2. These results suggest
that the epitope recognized by H18.K2 is sensitive to structural
changes resulting from deletion. In addition, the ELISA results suggest
that the structural change does not necessarily inhibit binding of H18.
K2 to the viral particle but only prevents its ability to neutralize
infection. Using the in vitro raft culture system and mutating one
methionine at a time may help us to identify the start codon(s) used
by the native virus. Although the L1 structure has been studied, the L2
structure is largely unknown.
In this study, we used a genetic approach to study HPV
morphogenesis and showed that the N-terminus of HPV18 L1
interfered with the cooperation between HPV18 L1 and HPV16 L2
during virion morphogenesis. After deleting the 35 amino acids in
HPV18 L1 N-terminus, infectious virus production was greatly
improved. Since HPV18 virus can be efﬁciently produced with or
without the ﬁrst 35 amino acids, its potential role in viral life cycle
is intriguing. In addition, because most available conformation-
dependent antibodies were raised against PV L1 VLPs, atomic
structure analysis of VLPs combined with immunological studies
using our chimeric viruses may also help us to better understand the
similarities and differences between VLPs and authentic virions.
Materials and methods
Plasmid construction
HPV18 DNA, a generous gift from Harold zur Hausen, was cloned
into pBluescript SK(+) [pBSSK(+)] (Stratagene, La Jolla, CA) at the
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pBSHPV18 was used as a template to separately amplify the L2 and L1
ORFs using primers 18a5′, 18L2gHin, 18L1hHin, and 18hBgl (Table 1).
The HPV16 L2/L1 ORFs were BglII digested out of the HPV18/16
chimeric genome (Meyers et al., 2002) and ligated into the BglII site of
the pGL2 Basic Vector (Promega, Madison, WI) to make pGL216L2/L1.
The electroporation protocol requires the release of the HPV genomic
DNA from the vector DNA sequences. Since the HPV18 genomic DNA
was cloned into the vector DNA at the EcoRI site, it was necessary to
mutate the EcoRI site contained within the HPV16 L1 ORF at 6819
(Meyers et al., 2002). Using pGL216L2/L1 as a template the HPV16 L2
and L1 ORFs were separately ampliﬁed using primers 16c5′, 16L2cHin,
16L1fHin, and 16L1fBgl (Table 1). Each ampliﬁed ORF was cloned
individually into the pCR2.1 vector (Invitrogen, Eugene, OR) using the
TOPO TA cloning procedure according to the manufacturer's instruc-
tions (Invitrogen). Each capsid ORF was then individually cloned into
pBSSK+vectors. The plasmid pBSHPV18ΔL2/L1 contains a HPV18
genomewith its L2 and L1 ORFs removed and replaced with a BglII site
in a pBSSK(+) vector (Meyers et al., 2002). pBSHPV18ΔL2/L1 was
linearized by digesting with BglII, the HPV18 and HPV16 capsid ORFs
were separated from the pBSSK+vector following digestion with
BglII and HindIII, and each combination of L2 and L1 ORFs was cloned
into the linearized pBSHPV18ΔL2/L1 plasmid as shown in Fig. S1. All
mutant genomes were analyzed by restriction digestion and
sequenced to ensure they were correct.
Each half (N-terminal and C-terminal) of the HPV18 and HPV16 L2
and L1 ORFs were PCR ampliﬁed using primers B1-4, C1-4, E1-4,
and F1-4 (Table 1) as shown in Fig. S2. This created N-terminal and
C-terminal halves with the N-termini of the L2 ORFs and the C-termini
of the L1 ORFs containing a BglII (BII) restriction site, and the C-termini
of the L2 ORFs and the N-termini of the L1 ORFs containing a HindIII
(HIII) restriction site. The other end of each ampliﬁed sequence
contained a SapI (SI) restriction site. Each ampliﬁed sequence was then
digested with BglII and SapI or HindIII and SapI as appropriate and
isolated. To create chimeric L2 or L1 ORFs, the N-termini and C-termini
of HPV18 L2 and L1 ORFs were ligated to the N-termini and C-termini of
HPV16 L2 and L1 ORFs, respectively, and with the pGL2 vector that was
previously linearized by double digestion with BglII and HindIII
(Fig. S2). Restriction digests and sequencing were performed to verify
the chimeric capsid ORFs. Following digestionwith BglII andHindIII, the
chimeric capsid ORFs were separated and isolated from the pGL2
vector. Wild-type HPV18 and HPV16 L2 and L1 ORFs were separated
and isolated from the HPV18-L2(18)L1(18) and HPV18-L2(16)L1(16).
A chimeric L2 or L1 ORF was then ligated with a wild-type L1 or L2 ORF
along with pHPV18L2/L1Δ that had been previously digested with BglII
and HindIII (Fig. S2). This produced eight chimeric virus genomes as
shown in Fig. S2. We designated the resulting chimeric plasmids as
HPV18-L2(18)L1(16/18), HPV18-L2(18)L1(18/16), HPV18-L2(16)L1
(16/18), HPV18-L2(16)L1(18/16), HPV18-L2(16/18)L1(18), HPV18-
L2(16/18)L1(16), HPV18-L2(18/16)L1(18), and HPV18-L2(18/16)L1
(16) (Fig. S2). All mutant genomes were analyzed by restriction
digestion and sequenced to ensure they were correct.
The HPV18/HPV16 L2 chimeras form a junction in the homologous
sequence, LITYDNPA, which corresponds to amino acids 249–256 in
HPV16 and amino acids 248–255 in HPV18. The HPV18/HPV16 L1
chimeras form a junction in the homologous sequence, LRREQ,
which corresponds to amino acids 276–280 in HPV16 and amino
acids 311–315 in HPV18. The amino acid difference in numbering for
the L1 and L2 proteins is due to gaps inserted when the HPV18 and
HPV16 sequences were lined up according to their homologies. The
homologous sequences that form the junction site for the L2 and L1
chimeras are approximately in the middle of each ORF.
To create viral genomes containing a HPV18 L1 with the N-terminal
ﬁrst 35 amino acids deleted, primers N-35 and F4 (Table 1)were used to
PCR amplify the ORF sequence lacking the ﬁrst 105 nt (Fig. S3). Primer
N-35maintained the start sequence ATG and added a BamHII site on the5′ end and the F4 primer added a BglII site on the 3′ end. This amplimer
was then digested with BamHII and BglII and was ligated into the
pHPV18L1/L2Δ plasmid that was previously digested with BamHII and
BglII along with one of the following wild-type or chimeric L2 ORFs:
18 L2, 16 L2, 18/16 L2, or 16/18 L2 (Fig. S3). This create four mutant
viral genomes, HPV18-L2(18)L1(Δ18), HPV18-L2(16)L1(Δ18), HPV18-
L2(18/16)L1(Δ18), and HPV18-L2(16/18)L1(Δ18) (Fig. S3). All mutant
genomes were analyzed by restriction digestion and sequenced to
ensure they were correct.
Western blot analysis
One hundred-microliter aliquots of protein extracts were trans-
ferred into a 1.5-ml microfuge tube, followed by adding 100 μl of
buffer A (50 mM NaPO4 (pH 7.2), 5 mM EDTA, 50 mM NaF, 0.5 μg/ml
leupeptin, 0.5 μg/ml pepstatin, 20 μg/ml aprotinin, 0.2 mM Na3VO4,
1 mM DTT, 1 mM PMSF). To this suspension, 200 μl of buffer B was
added (identical to buffer A but supplemented with 2% wt./vol. SDS)
and boiled in a water bath for 8 min. While boiling, the samples were
vortexed for 2 min. To each sample, 125 μl of 5× sample loading buffer
was added (100 mM Tris, pH 8.0, 5 mM EDTA, 10% (wt./vol.) sucrose,
2% (wt./vol.) SDS, 33 mM DTT, and 0.1 mg/ml Pyronin Y). Total
protein concentrations were measured using the Peterson protein
assay (Lowry method) as previously described (Meyers et al., 2001).
To determine capsid protein expression, 90 and 120 μg of the extracts
were loaded onto 7.5 % SDS–PAGE gels. Proteins were transferred to a
nitrocellulose membrane (Protran; Schleicher & Schuell). Membranes
were incubated overnight with primary monoclonal antibodies
(kindly provided by Dr. Neil Christensen, Penn State College of
Medicine), H18.E20 (L1-reactive) (Rizk et al., 2008), H18.L9 (L1-
reactive) (Bishop et al., 2007), and H16.4B4 (L2-reactive) (Embers et
al., 2004). All three monoclonals cross-react with their respective
capsid proteins from HPV18 and HPV16 but not with CRPV. After
being washed, the blots were incubated with anti-mouse horseradish
peroxidase linked secondary antibody (Amersham Life Science) as per
the manufacturer's instructions. The proteins were detected using the
enhanced chemiluminescence method (Perkin-Elmer) as per the
manufacturer's instructions.
Electroporation and maintenance of keratinocyte
Primary human foreskin keratinocyte (HFK) cultures were derived
from newborn foreskin via trypsin digestion at 37 °C as previously
described (Meyers, 1996). HFKs were maintained in monolayer
cultures without feeder cells, with 154 medium (Cascade Biologics,
Portland, OR), supplemented with antibiotics (Cascade Biologics) and
human keratinocyte growth supplement (Cascade Biologics). Multiple
batches of primary human foreskin keratinocytes were electroporated
with each mutant genome as previously described (Meyers et al.,
2002).
Organotypic raft cultures and histochemical analyses
Organotypic raft cultures were grown as previously described
(Meyers et al., 2002). Once at the air–liquid interface the raft cultures
were fed by diffusion from below every other day with E medium
lacking EGF supplemented with 10 μM 1,2-dioctanoyl-sn-glycerol
(C8; Sigma Chemical Co.). Raft cultures were allowed to stratify and
differentiate for 12 days because viral gene expression has been
shown to peak between 10 and 12 days in the raft system (Ozbun and
Meyers, 1999a; Ozbun and Meyers, 1997; Ozbun and Meyers, 1998a,
b; Ozbun and Meyers, 1999b). For histochemical analyses, harvested
raft tissues were ﬁxed in 10% neutral-buffered formalin and were
embedded in parafﬁn. Four-micrometer sections were cut and stained
with hematoxylin and eosin.
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Viral DNA was isolated as previously described (Meyers et al.,
2002). Five micrograms of total cellular DNA from each sample was
digested with either EcoRI, to linearize the viral genomes, or BglII, to
separate the structural genes from nonstructural genes, or left
undigested and then electrophoresed in a 0.8% agarose gel and
transferred onto a GeneScreen Plus membrane (New England Nuclear
Research Products, Boston,MA) as previously described (Meyers et al.,
2002). Southern blot hybridization was performed as previously
described (Meyers et al., 2002). The HPV DNA probes were prepared
by gel puriﬁcation of the 8 kb HPV and labeled with the Random
Primed DNA labeling kit (Roche Molecular Biochemicals, Indianapolis,
IN). Labeled probe was puriﬁed with a Quick Spin Column for
radiolabeled DNA puriﬁcation (Roche Molecular Biochemicals). Blots
were probed ﬁrst with a complete HPV18 genomic probe and then
were stripped and reprobed with a complete HPV16 genomic probe.
Stripping of a membrane was accomplished by placing the blots in
0.1× SSC (1× SSC is 0.15 M NaCl plus 0.015 M sodium citrate)–1%
sodium dodecyl sulfate and boiling for 1 h.
Preparation of virus stocks
Virus stocks were prepared by peeling the epithelial tissue away
from the collagen of three organotypic rafts for each HPV chimera. The
peeled epithelial layers were homogenized in 0.6 ml of ice-cold 1 M
NaCl/0.05 M Na-Phosphate Buffer with a 7.5-ml homogenizer.
The homogenizer was washed twice with 200 µl 1 M NaCl/0.05 M
Na–phosphate buffer, pH 8. The homogenized viral solution was
centrifuged at 10.5 k for 10 min at 4 °C, and the supernatant was
transferred to a 1.8-ml Nalgene cryovial. The virus stocks were stored
at −20 °C.
HPV infection and neutralization assays
The infectivity measurement of chimeric HPV used the limited
dilution RT–PCR titering assay as described previously (Alam et al.,
2008; Conway et al., 2009a,b; McLaughlin-Drubin et al., 2004;
McLaughlin-Drubin and Meyers, 2004; McLaughlin-Drubin and
Meyers, 2005; McLaughlin-Drubin et al., 2003; Meyers et al., 2002;
Meyers et al., 1997) using HaCaT cells, an immortalized human
keratinocyte cell line (kindly provided by Norbert Fusenig). The virus
titer was determined to be the last dilution at which the spliced
transcript could be detected.
Infectivity neutralization assays were performed by infecting
HaCaT cells with a 1:20 diluted viral sample that had been
preincubatedwith type-speciﬁcmonoclonal antibodies (mAb) diluted
1:20 in HaCaT culture medium as previously described (Conway et al.,
2009a,b; McLaughlin-Drubin et al., 2004; McLaughlin-Drubin and
Meyers, 2005; McLaughlin-Drubin et al., 2003). The type-speciﬁc
antibodies included L1-reactive conformation-dependent monoclonal
antibodies, H18.J4 and H18.K2. Both of these antibodies were
previously characterized (Bishop et al., 2007). Following preincuba-
tion, HaCaT cells were infected with the virus–antibody mixture and
incubated for 2 days as described.
ELISA
Fivemicroliters of HPV stockswas bound per well to 96-well plates
overnight at 4 °C in neutral PBS buffer, washed, and blocked for 2 h
with 5% nonfat milk in PBS. Conformation-dependent HPV18 L1-
reactivemonoclonal antibodies H18.J4 and H18.K2 Bishop et al., 2007)
were used in ELISA studies. Wells containing HPV mutants were
incubatedwithmAbs diluted 1:100 in blocking buffer for 1 h, followed
by incubation with rabbit anti-mouse-AP (Pierce) at 1:1000 and
development with 1 mg/ml p-nitrophenyl phosphate substrate(Sigma). Wells probed with a negative control mAb H11.B2 (a
HPV11 L1 conformation-dependent, neutralizing mAb) were read and
used as background values for comparison. Absorbance at 405 nm
(A405) was measured via a microplate reader (ThermoLabsystems).
The readings from wells probed with capsid-speciﬁc mAb minus the
readings from wells probed with the negative control mAb was
deﬁned as the speciﬁc binding to each mutant HPV.
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